Record mula sa primary source

MateryalPagbabago sa trial registry

AN2 Therapeutics: Global Phase 2 epetraborole PV study cleared; enrollment by end-2026

Natanggap ng AN2 Therapeutics ang pag-clear ng FDA IND at mga pag-apruba sa regulasyon sa Australia at India para sa kanilang global Phase 2 study ng oral epetraborole sa phlebotomy-dependent polycythemia vera. Kasalukuyang isinasagawa ang mga startup activities na may inaasahang pagsisimula ng enrollment sa pagtatapos ng taon 2026, na nagsisimula sa isang sentinel cohort.

Mahahalagang fact

Na-file
Nob 9, 2026, 12:30 PM
Kaganapan
Pagbabago sa trial registry
Direksyon
Neutral
Kumpiyansa
May source

Sipi mula sa source

AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights Global Phase 2 study of oral epetraborole in polycythemia vera (PV) cleared to proceed in all planned jurisdictions; expect to initiate enrollment by year-end Enrollment ongoing in Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung disease Advancing startup activities for Phase 2 study of AN2-502998 in chronic Chagas disease AN2-504661 selected as oral development candidate for hypophosphatasia (HPP) Extended third-party funding supports AN2

Press release ng kumpanya

Higit pa tungkol sa asset na ito

Okt 21, 2026
11:00 AM
ANTXAN2 Therapeutics

AN2 Therapeutics upang I-presenta ang Disenyo ng Phase 2 Epetraborole sa PV sa MPN Congress

Presentasyon sa kumperensyaPress release ng kumpanya
Mar 17, 2026
08:02 PM
ANTXAN2 Therapeutics

AN2 Therapeutics sisimulan ang Phase 2 epetraborole PV trial 3Q26

Pagbabago sa trial registrySEC 8-K
AN2 Therapeutics: Global Phase 2 epetraborole PV study cleared; enrollment by end-2026 | SimianX AI